Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

April 30, 2002

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

BIOLOGICAL

recombinant interleukin-12

DRUG

etoposide

DRUG

ifosfamide

Trial Locations (10)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

10029

Mount Sinai School of Medicine, New York

33136

Sylvester Cancer Center, University of Miami, Miami

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

60611

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

94110

San Francisco General Hospital Medical Center, San Francisco

90033-0800

USC/Norris Comprehensive Cancer Center, Los Angeles

02114-2617

Massachusetts General Hospital, Boston

07103

University Hospital/New Jersey Cancer Center, Newark

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003575 - Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter